Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC-study) - a Phase I/II Trial

Next Previous
Trial Profile

Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC-study) - a Phase I/II Trial

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2018

At a glance

  • Drugs Nivolumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Adenocarcinoma; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Acronyms INEC

    • Most Recent Events

    • 06 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top